Pharmaceuticals

搜索文档
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
ZACKS· 2025-08-01 21:50
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...
LENZ Therapeutics (LENZ) Update / Briefing Transcript
2025-08-01 21:00
LENZ Therapeutics (LENZ) Update / Briefing August 01, 2025 08:00 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the LENS Therapeutics Corporate Update Conference Call. At this time, all participants are in a listen only mode. Following prepared remarks from management, we will conduct question and answer session and instructions will follow at that time. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Dan Chief Financial Officer.Please go ahe ...
Regeneron(REGN) - 2025 Q2 - Earnings Call Presentation
2025-08-01 20:30
Regeneron Corporate Presentation A U G U S T 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may di ...
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
ZACKS· 2025-08-01 20:16
宽护城河投资策略 - 该策略聚焦于行业领先且具备持久竞争优势的公司 这些公司通过品牌认知 专利保护 专有技术和网络效应构建护城河 确保长期盈利能力和市场领导地位 [2][3] - 策略目标并非短期收益 而是构建能抵御经济波动 提供稳定可预测回报的投资组合 [2] - 推荐五家具备Zacks Rank 2评级的宽护城河公司:Adobe 迪士尼 Intuit Rollins和强生 [4] 公司分析 Adobe (ADBE) - 在Photoshop Illustrator等旗舰产品中广泛应用AI技术 推出生成式AI工具Adobe Firefly和AI助手Acrobat Reader [7] - 通过AI驱动的云平台拓展数字营销服务 提供数据挖掘和跨设备个性化体验 [8] - 推出基于AI的Adobe Express应用 支持iOS/Android平台短视频编辑 [9] - 2025财年预期收入增长9.5% 盈利增长12% 过去30天盈利预期上调0.1% [11] 迪士尼 (DIS) - 国内主题公园 迪士尼度假俱乐部和邮轮业务推动收入增长 部分被上海和香港迪士尼的疲软抵消 [12] - 娱乐业务预计2025财年运营收入实现两位数增长 ESPN平台18-49岁观众群收视率增长32% [13] - 流媒体业务扭亏为盈 2025Q2直接面向消费者(DTC)运营收入达3.36亿美元 [14] - 2025财年预期收入增长4.1% 盈利增长16.3% 过去60天盈利预期上调0.3% [15] Intuit (INTU) - 在线服务和桌面业务收入稳健 Mailchimp 薪资和支付业务表现强劲 [16] - 推出生成式AI工具"Intuit Assist" 集成至TurboTax QuickBooks等产品 [17] - Credit Karma业务在信用卡 汽车保险等领域表现良好 云订阅模式转型助力长期收入稳定 [18] - 2026财年预期收入增长11.7% 盈利增长13.7% 过去90天盈利预期上调4.3% [19] Rollins (ROL) - 通过BOSS Orkin 2.0等技术工具优化运营 降低成本 VRM和BizSuite系统提升调度效率 [20] - 2024年完成44起收购 零债务且现金流充裕 持续提高股息 [20] - 当前财年预期收入增长10.7% 盈利增长12.1% 过去7天盈利预期上调0.9% [21] 强生 (JNJ) - 创新药业务增长显著 主要产品Darzalex Tremfya等表现强劲 新药Spravato快速放量 [22][23] - 医疗器械业务受中国市场逆风和竞争压力影响 但心血管板块贡献增长 预计下半年两大业务增速提升 [23] - 当前财年预期收入增长5.2% 盈利增长8.8% 过去7天盈利预期上调0.1% [24] 行业趋势 - 五家公司均具备宽护城河商业模式 预计在2025下半年展现强劲潜力 [10] - 各公司盈利和收入增长预期稳健 盈利预测持续上调 [10] - AI工具 强势品牌和战略收购构成长期竞争优势的核心要素 [10]
逆势涨停潮!中药板块要起飞?机构最新解读
天天基金网· 2025-08-01 20:01
中药板块市场表现 - 8月1日中药板块逆势拉升 多股涨停 其中生物谷涨超20% 维康药业20CM涨停 贵州百灵 天目药业 新天药业等涨停封板 [6] - 机构研报指出中药OTC受库存周期扰动出现边际拐点 建议关注精品+创新两大主线 [1][6] 中药行业投资主线 - 精品中药兼具医疗价值与消费属性 代表企业包括同仁堂 东阿阿胶 健民集团 云南白药等 [2] - 创新中药在政策支持与外部环境刺激下进入收获期 相关企业包括康缘药业 珍宝岛 济川药业 天士力 以岭药业等 [2][6] 机构观点汇总 - 中信证券指出中成药集采涉及品种占市场规模20%-30% 未来将持续扩围 院外市场品牌集中度提升 2025Q2后零售端库存进入健康状态 [7] - 华福证券认为中药板块一季度高基数压力出清 当前估值低配 2025年二至三季度业绩将逐季改善 [7] - 华金证券表示短期关注库存拐点+线上渠道突破 中期看成本改善+高股息 长期受政策基药 创新药及老龄化需求驱动 [8] 相关基金产品 - 前海开源中药股票A 汇添富中证中药ETF联接(LOF)A 鹏华中证中药ETF联接C等基金与中药板块关联密切 [3]
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
Globenewswire· 2025-08-01 19:45
MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access PathwaySOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK’s Medi ...
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
GlobeNewswire News Room· 2025-08-01 19:45
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinica ...
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
Globenewswire· 2025-08-01 19:30
MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, August 7, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-888-699-1199 or Internationa ...
华特达因:子公司签署褪黑素颗粒(曼乐静)总经销合同
格隆汇APP· 2025-08-01 17:20
格隆汇8月1日丨华特达因(000915.SZ)公告称,子公司北京达因康健与日本诺贝仁制药株式会社就褪黑 素颗粒(曼乐静®)在中国大陆地区的独家总经销事宜达成一致,并签署《褪黑素颗粒总经销协议》。达 因康健将成为该产品在中国大陆地区(不含港澳台)的独家总经销商。该产品于2025年7月在中国获批 上市,商品名为"曼乐静®"。该产品是我国首个获批用于治疗6-15岁神经发育障碍儿童入睡困难的褪黑 素制剂,同时也是褪黑素类物质在国内首次以药品身份获得上市许可。 ...
速递|特朗普施压17家药企CEO:限期降低美国药价
GLP1减重宝典· 2025-08-01 16:32
整理 | GLP1减重宝典内容团队 受此消息影响,多家药企股价当日下跌,其中辉瑞、礼来和吉利德科学跌幅约2%,纽约泛美制药指数下跌3%。 特朗普在信中提出明确要求:所有药企必须向美国政府医疗补助项目(Medicaid)的患者提供"最惠国价格",即OECD国家中最低的定 价。此外,新药也应执行相同政策。同时,企业需承诺不得向其他发达国家提供低于美国的售价。 他还要求企业将因国外高定价而获得的超额利润返还给美国患者和纳税人,方式是与政府签订返还协议。为打击中间商加价行为,特朗 普还提出支持企业直接面向患者销售药品,但前提是执行"最惠国"定价。 美国总统特朗普日前向17家大型制药企业的首席执行官发出公开信,要求他们将美国处方药的价格降低至与国际市场接轨,尤其是与其 他发达国家一致。白宫证实,这一行动是特朗普行政命令的一部分,旨在压制美国持续高企的药品费用。 今年5月,特朗普签署了一项行政命令,要求药企将药品价格与国际最低价格对齐,否则政府将通过立法、行政规则,甚至允许从海外 进口低价药品等手段干预市场。 收到信件的企业包括礼来、赛诺菲、再生元、默沙东、强生、阿斯利康等全球领先的制药公司。特朗普在信中表示:"大多数药 ...